-
Product Insights
Graves' Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graves’ Ophthalmopathy Pipeline Drugs Market Report Overview Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ ophthalmopathy. Symptoms include eye redness, inflammation, eyelid retraction, and weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery. The Graves’ Opththalmopathy pipeline drugs market research report provides comprehensive information on...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Presbyopia Pipeline Drugs Market Report Overview Presbyopia is an eye condition in which the eye slowly loses the ability to focus quickly on close objects. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print, and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis, and eye trauma. The Presbyopia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by...
-
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The Age...
-
Sector Analysis
Dry Eye Syndrome Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2018-2028
Dry Eye Syndrome Market Report Overview The Dry Eye Syndrome (DES) market size across the 7MM was valued at $3.4 billion in 2018 and is forecast to grow at a CAGR of more than 11% during 2018-2028. The Dry Eye Syndrome market research report provides an overview of DES, including epidemiology, pathophysiology, diagnosis, and disease management. Dry Eye Syndrome Market Outlook To gain more information on the dry eye syndrome market forecast, download a free report sample
-
Product Insights
Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Macular Edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as...
-
Product Insights
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinal Vein Occlusion is a blockage in one of the veins returning blood flow from the retina. Its predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion pipeline market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Sector Analysis
Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glaucoma represents a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs). It is the leading cause of irreversible vision loss worldwide. The Glaucoma marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in Glaucoma therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood...
-
Product Insights
Ocular Hypertension Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Ocular Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Ocular Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Ocular Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Retinal Vein Occlusion Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Retinal Vein Occlusion Global Clinical Trials Review, H2, 2016" provides an overview of Retinal Vein Occlusion clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.